PTC says it will make changes to the price after abandoned launch last month.
Activist investor’s intervention adds to buzz surrounding BMS.
Company reports better than expected full year figures.
Speculation mounting that Pfizer and others could try for $90 bn plus merger
PRAC to review Uptravi after five deaths in France.
Company needs to make acquisition to grow, admits CEO.